Description: Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncology and neurological diseases. The company's lead application is Telo-MM, a solution that provides actionable information to medical professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient's telomeres. The company serves pathologists, clinicians, academic researchers, and drug developers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. was incorporated in 2011 and is headquartered in Toronto, Canada.
Home Page: www.telodx.com
MaRS Centre
Toronto,
ON
M5G 1L7
Canada
Phone:
416 673 8487
Officers
| Name | Title |
|---|---|
| Dr. Sherif Louis MSc, Ph.D., PMP | Pres & CTO |
| Dr. Sabine Mai Ph.D. | Founder, Member of Clinical & Scientific Advisory Board and Director |
| Mr. Christopher Ross CPA, CGA | Chief Financial Officer |
| Mr. Kristan Joseph Weinberg | Chief Exec. Officer |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Technology |
| GIC Sub-Industry: | Health Care Technology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 10.4566 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |